Navigation Links
Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers. These three cancers represent approximately 50% of all cancers that occur in the pediatric population.

Patients with advanced cancers who have failed current therapy will be eligible to be treated with ADI-PEG 20. In addition, a tumor specimen from these potentially eligible patients must be deficient in expression of the enzyme argininosuccinate synthetase, the rate limiting step in formation of arginine. Patients will be enrolled into cohorts of increased doses of ADI-PEG 20, and will receive weekly intramuscular injections of ADI-PEG 20 until disease progression.  The primary endpoints of the study are safety and efficacy, and secondary endpoints will include finding the maximum tolerated dose of ADI-PEG 20 in a pediatric tumor population.

The rationale for the use of ADI-PEG 20 in these cancers was previously reported by Polaris collaborators, using both cell based assays and xenograft mouse models. In addition, they found a high percentage of these cancer tissue specimens require arginine. This Phase 1 clinical study is being conducted at MD Anderson Cancer Center, Houston, Texas.

"We are delighted to begin this first study of ADI-PEG 20 in pediatric patients," said John Bomalaski, M.D., Executive Vice President, Medical Affairs, of Polaris. "We believe ADI-PEG 20 is a promising cancer therapeutic for these cancers, and we plan to initiate Phase 2 studies in adults with these cancers. ADI-PEG 20 as monotherapy is already in a Phase 3 global trial for patients with hepatocellular carcinoma, and in Phase 2 trials for patients with small cell lung carcinoma and mesothelioma. In addition, a Phase 1 trial in prostate cancer
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
3. Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer
4. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
5. Winner Medical Group Inc. to Host First Quarter 2012 Earnings Conference Call on Thursday, February 9, 2012 at 08:00 p.m. EST
6. Concord Medical Services Holdings Limited Engages Solebury Communications Group LLC to Establish a Strategic Investor Relations Program
7. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
8. Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry
9. MiMedx Group, Inc. Board Announces Support for Chairman Parker H. "Pete" Petit
10. The Zacks Analyst Blog Highlights: UnitedHealth Group, Aetna, WellPoint, CIGNA and Wright Medical Group
11. MiMedx Group, Inc. to Present at the Noble Capital Markets 8th Annual Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 26, 2011 Galleon Pharmaceuticals, a leader in the ... board of directors has elected Thomas J. Dietz, Ph.D., ... CEO of Waypoint Holdings, LLC, a diversified financial-holdings and ... was co-CEO and then CEO and a director of ...
... Oct. 26, 2011 Reportlinker.com announces that ... in its catalogue: Wheelchair ... to 2015 http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... 484 pages, 235 tables and figures. Worldwide ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... care to properly heal , ... ... On the one-year anniversary of the massive earthquake that devastated ... education and humanitarian assistance organization, is officially launching the China ...
... Health Organization urge vigilance against the "swine flu" (Type A influenza ... Huff, recommends practical tips for protecting your young child and baby ... ... Asheville, NC (PRWEB) May 12, 2009 -- The World Health Organization ...
... Chairman of the,Avon Foundation for Women, today joined ... Women leaders for a day of events to ... Breast Center at the San,Francisco General Hospital and ... making progress possible in breast cancer research and,care. ...
... Tenn., May 11 Brookdale Senior Living Inc. (NYSE: ... Executive Officer, and Mark Ohlendorf, Co-President and Chief Financial Officer, ... of America and Merrill Lynch 2009 Health Care Conference in ... 10:00 a.m. Eastern Time.The presentation is being audio webcast live ...
... Entity for Topical Acne Treatment in a DecadeCARLSBAD, Calif., May ... entered into a co-promotion agreement with Allergan for ACZONE(R) ... Representing the first new molecule in a decade approved by ... 12 years of age and older, ACZONE(R) Gel 5% combines ...
... following statement is from Regence BlueCross BlueShield President and CEO ... by a group of private-sector health industry leaders to decrease ... as much as $2 trillion over the next ten years:"I ... costs in our nation. We are a country that ...
Cached Medicine News:Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 2Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 3Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 2Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 3Health News:MultiVu Video Feed: REESE WITHERSPOON JOINS AVON FOUNDATION FOR WOMEN AND SAN FRANCISCO GENERAL HOSPITAL TO CELEBRATE 5TH ANNIVERSARY OF AVON COMPREHENSIVE BREAST CENTER 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 3Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 4Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: